NOVAREX

• MPOD for subjects in both 12mg and supplementation groups increased significantly versus placebo at both 6-and 12-month visits (p<0.001 for all).
  PSR times and DG thresholds improved significantly from baseline compared to placebo at 6-and 12-month visits (p<0.001 for all).

Fig.1 Percent change from baseline at 6 and 12 months for all outline mreaures. Error bars±1 SD.Single astrisk denotes significant difference from baseline and placebo (p<0.05 level);double asterisk denotes significant differences from baseline,6-month measure, and placebo(p<0.05 level)

• Lutemax2020 suplementation(24 mg daily)yielded significant improvement in MOPD,overall sleep quality, headache frequency, eye strain, eye fatigue,and all visual performance measures, versus placebo(p<0.05 for all).

Macular pigment optical density(MPOD)

After 6 months of lutein and Zeaxanthin 24mg intake, MOPD, DG(glare tolerance) and PSR(speed of recovery after glare) were significantly improved.

Effect on the body

After 6 moths of lutein Zeaxanthin 24 mg intake, headache,eye fatigue and sleep disorders were significantly improved.

• Compared to placebo, serum concentrations of lutein and total zeaxanthin, for each of the supplement levels, were found increase signicantly from baseline after teo weeks of daily ingestion(p<0.001).Likewise,MOPD increased signicantly in all treatment groups(p<0.001)compared to placebo.

Lutein Concentration in Serum

Zeaxanthin concentration in serum

Macular Pigment Optical Density(MOPD)

• MOPD increased significantly from baseline to month 3 increased for all L/Zi treatments over placebo.
  significant change in MOPD was observed in Group â…¢ and â…£ at week 8 to week 12(p<0.001>.

Table 2. MPOD (OD Units) Response by Week and Dose (Mean ± SD).

• · MPOD : Macular Pigment Optical Density;
• · OD : Optical Density